What share class is referenced in GSK’s (GSK) total voting rights announcement?

The announcement refers to GSK’s ordinary shares of 31 ¼ pence each. These ordinary shares form the company’s issued share capital, with some held in treasury and the remainder representing the total voting rights available to shareholders.

GSK updates total voting rights and share capital

Q: What is the total number of GSK (GSK) voting rights as of 28 February 2026?

GSK reports a total of 4,072,135,394 voting rights as of 28 February 2026. This figure excludes treasury shares and is the reference number shareholders use to assess disclosure thresholds under UK transparency rules.

Q: How many GSK (GSK) ordinary shares are in issue and held in treasury?

GSK had 4,316,162,488 issued ordinary shares of 31 ¼ pence each as of 28 February 2026, of which 244,027,094 shares were held in treasury. Treasury shares are issued but do not carry voting rights while held by the company.

Q: How can GSK (GSK) shareholders notify the company of major shareholdings?

Shareholders can send major shareholding notifications to company.secretary@gsk.com. They use the disclosed total voting rights figure as the denominator to calculate whether their ownership level or changes trigger reporting under UK disclosure and transparency requirements.

Q: What is the purpose of GSK’s (GSK) March 2026 Form 6-K?

The March 2026 Form 6-K provides an update on issued share capital and voting rights. It confirms the total ordinary shares, treasury holdings, and resulting voting rights so investors can accurately assess regulatory disclosure thresholds for their shareholdings.

GSK plc reports its share capital and voting rights position as of 28 February 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reports its share capital and voting rights position as of 28 February 2026. The company had 4,316,162,488 issued ordinary shares of 31 ¼ pence each, with 244,027,094 of these held in treasury. Shares held in treasury do not carry voting rights.

After excluding treasury shares, the total number of voting rights in GSK is 4,072,135,394. Shareholders can use this figure as the denominator when calculating whether they must notify the company and the UK regulator of any interests or changes in their holdings.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the total number of GSK (GSK) voting rights as of 28 February 2026?

GSK reports a total of 4,072,135,394 voting rights as of 28 February 2026. This figure excludes treasury shares and is the reference number shareholders use to assess disclosure thresholds under UK transparency rules.

How many GSK (GSK) ordinary shares are in issue and held in treasury?

GSK had 4,316,162,488 issued ordinary shares of 31 ¼ pence each as of 28 February 2026, of which 244,027,094 shares were held in treasury. Treasury shares are issued but do not carry voting rights while held by the company.

Why does GSK (GSK) disclose its total voting rights figure?

GSK discloses its total voting rights to help investors comply with Financial Conduct Authority transparency rules. The stated voting rights number is used as the denominator when investors calculate if they must notify holdings or changes in their interest.

How can GSK (GSK) shareholders notify the company of major shareholdings?

Shareholders can send major shareholding notifications to company.secretary@gsk.com. They use the disclosed total voting rights figure as the denominator to calculate whether their ownership level or changes trigger reporting under UK disclosure and transparency requirements.

What is the purpose of GSK’s (GSK) March 2026 Form 6-K?

The March 2026 Form 6-K provides an update on issued share capital and voting rights. It confirms the total ordinary shares, treasury holdings, and resulting voting rights so investors can accurately assess regulatory disclosure thresholds for their shareholdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/02/2026 - 12:29 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 2 March 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 28 February 2026 consisted of 4,316,162,488 shares of 31 ¼ pence each ('Ordinary Shares'), of which 244,027,094 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,072,135,394. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

2 March 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: March 02, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR